Modi, A A <br/><br/>
Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir.  [electronic resource] 

 -  Alimentary pharmacology & therapeutics  05 2018 
 - 1409-1415 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1365-2036 
<br/><br/><label>Standard No.: </label>10.1111/apt.14604  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abdominal Pain--epidemiology<br/>Adult<br/>Aged<br/>Antiviral Agents--administration & dosage<br/>Benzimidazoles--administration & dosage<br/>Drug Therapy, Combination<br/>Esophageal and Gastric Varices--epidemiology<br/>Fatigue--chemically induced<br/>Female<br/>Fluorenes--administration & dosage<br/>Gastrointestinal Hemorrhage--epidemiology<br/>Genotype<br/>Hepacivirus--genetics<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Liver Cirrhosis--drug therapy<br/>Liver Transplantation<br/>Male<br/>Middle Aged<br/>Nausea--chemically induced<br/>Prospective Studies<br/>Ribavirin--administration & dosage<br/>Simeprevir--administration & dosage<br/>Sofosbuvir<br/>Sustained Virologic Response<br/>Uridine Monophosphate--administration & dosage